BR122018014454B8 - forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol - Google Patents
forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenolInfo
- Publication number
- BR122018014454B8 BR122018014454B8 BR122018014454A BR122018014454A BR122018014454B8 BR 122018014454 B8 BR122018014454 B8 BR 122018014454B8 BR 122018014454 A BR122018014454 A BR 122018014454A BR 122018014454 A BR122018014454 A BR 122018014454A BR 122018014454 B8 BR122018014454 B8 BR 122018014454B8
- Authority
- BR
- Brazil
- Prior art keywords
- methylpropyl
- dimethylamino
- ethyl
- phenol hydrochloride
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
formas cristalinas sólidas de cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol. a invenção se refere a uma nova forma cristalina de cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol, métodos para sua preparação e uso, e composições farmacêuticas que a contém.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04015091A EP1612203B1 (en) | 2004-06-28 | 2004-06-28 | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
BRPI0512792-0A BRPI0512792A (pt) | 2004-06-28 | 2005-06-27 | formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol |
PCT/EP2005/006884 WO2006000441A2 (en) | 2004-06-28 | 2005-06-27 | Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
BR122018014454B1 BR122018014454B1 (pt) | 2019-09-03 |
BR122018014454B8 true BR122018014454B8 (pt) | 2021-07-27 |
Family
ID=34925507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512792-0A BRPI0512792A (pt) | 2004-06-28 | 2005-06-27 | formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol |
BR122018014454A BR122018014454B8 (pt) | 2004-06-28 | 2005-06-27 | forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512792-0A BRPI0512792A (pt) | 2004-06-28 | 2005-06-27 | formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol |
Country Status (27)
Country | Link |
---|---|
US (16) | US20070213405A1 (pt) |
EP (2) | EP1612203B1 (pt) |
JP (1) | JP4990764B2 (pt) |
KR (1) | KR101096501B1 (pt) |
CN (1) | CN1997621B (pt) |
AR (2) | AR049949A1 (pt) |
AT (2) | ATE368639T1 (pt) |
AU (1) | AU2005256512B2 (pt) |
BR (2) | BRPI0512792A (pt) |
CA (1) | CA2572147C (pt) |
CY (2) | CY1106929T1 (pt) |
DE (2) | DE602004007905T2 (pt) |
DK (2) | DK1612203T3 (pt) |
EC (1) | ECSP17046065A (pt) |
ES (2) | ES2291780T3 (pt) |
HR (1) | HRP20110050T8 (pt) |
IL (1) | IL180373A (pt) |
MX (1) | MXPA06014741A (pt) |
NO (3) | NO338605B1 (pt) |
NZ (1) | NZ551605A (pt) |
PE (1) | PE20060372A1 (pt) |
PL (2) | PL1612203T3 (pt) |
PT (2) | PT1612203E (pt) |
RU (1) | RU2423345C2 (pt) |
SI (2) | SI1612203T1 (pt) |
WO (1) | WO2006000441A2 (pt) |
ZA (1) | ZA200700774B (pt) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DK1612203T3 (da) * | 2004-06-28 | 2007-12-03 | Gruenenthal Gmbh | Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
ES2623413T3 (es) * | 2007-12-07 | 2017-07-11 | Grünenthal GmbH | Modificaciones cristalinas de (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
EP2273983B1 (en) | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
PL2456424T3 (pl) | 2009-07-22 | 2013-12-31 | Gruenenthal Gmbh | Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania |
PL2456427T3 (pl) | 2009-07-22 | 2015-07-31 | Gruenenthal Gmbh | Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu |
US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
US20130116333A1 (en) | 2010-05-05 | 2013-05-09 | Ratiopharm Gmbh | Solid tapentadol in non-crystalline form |
KR102146233B1 (ko) | 2010-07-23 | 2020-08-21 | 그뤼넨탈 게엠베하 | 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀의 염 또는 공결정 |
AU2011297901B2 (en) | 2010-09-02 | 2014-07-31 | Grunenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
PT2680832T (pt) | 2011-03-04 | 2019-10-28 | Gruenenthal Gmbh | Formulação farmacêutica aquosa de tapentadol para administração oral |
RS56692B1 (sr) | 2011-03-04 | 2018-03-30 | Gruenenthal Gmbh | Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol |
HUE027514T2 (en) * | 2011-03-04 | 2016-10-28 | Gruenenthal Gmbh | Parenteral administration of tapentadol |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
PE20141638A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
WO2013120466A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A new solid form of tapentadol and a method of its preparation |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
EA201401139A1 (ru) | 2012-04-18 | 2015-03-31 | Грюненталь Гмбх | Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CZ304576B6 (cs) * | 2012-07-24 | 2014-07-16 | Zentiva, K.S. | Oxalát TAPENTADOLU a způsob jeho přípravy |
CN102924303B (zh) * | 2012-10-31 | 2013-11-20 | 合肥市新星医药化工有限公司 | 盐酸他喷他多晶型c及其制备方法和应用 |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
US9599565B1 (en) * | 2013-10-02 | 2017-03-21 | Ondax, Inc. | Identification and analysis of materials and molecular structures |
WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
PT3479823T (pt) | 2015-03-27 | 2020-09-29 | Gruenenthal Gmbh | Formulação estável para administração parentérica de tapentadol |
WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
PL3445742T3 (pl) | 2016-04-19 | 2020-05-18 | Ratiopharm Gmbh | Krystaliczny fosforan tapentadolu |
MX2019003257A (es) | 2016-09-23 | 2019-06-10 | Gruenenthal Gmbh | Formulacion estable para la administracion parenteral de tapentadol. |
EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
US11492342B2 (en) | 2020-11-03 | 2022-11-08 | Landos Biopharma, Inc. | Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
EP1283203A1 (en) * | 1996-08-14 | 2003-02-12 | G.D. Searle & Co. | Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide |
JP4180368B2 (ja) * | 2000-10-31 | 2008-11-12 | サンド・アクチエンゲゼルシヤフト | 塩酸ベンラファキシンの結晶形 |
US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
EP1426355B1 (en) * | 2001-09-13 | 2008-10-15 | Kissei Pharmaceutical Co., Ltd. | Crystals of hydroxynorephedrine derivative |
PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
DK1612203T3 (da) * | 2004-06-28 | 2007-12-03 | Gruenenthal Gmbh | Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid |
-
2004
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/en not_active Expired - Lifetime
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
-
2005
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en active Application Filing
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en active Active
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es active Active
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 CA CA2572147A patent/CA2572147C/en active Active
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en unknown
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja active Active
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de active Active
- 2005-06-27 EP EP05770026A patent/EP1799633B1/en active Active
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko active Protection Beyond IP Right Term
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
-
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
-
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
-
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
-
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en active Active
-
2011
- 2011-01-24 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
-
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
-
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
-
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
-
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
-
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
-
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
-
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es unknown
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
-
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
-
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
-
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122018014454B8 (pt) | forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
NO20171811A1 (no) | Fremgangsmåte for fremstilling av (1R,2R)-3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol | |
CR8717A (es) | Nuevos compuestos | |
AR058753A1 (es) | Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol | |
CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
DK2101569T3 (da) | Krystallinsk fast rasagilinbase | |
CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
BRPI0516464B8 (pt) | método para a preparação de um produto farmacêutico | |
ECSP10010661A (es) | Dronedarona para la prevención de la cardioversión | |
UY28762A1 (es) | Nuevos compuestos | |
BRPI0511819A (pt) | sais de guanilidrazona, composições, processos de fabricação e métodos de uso | |
EA200701180A1 (ru) | Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств | |
CL2011001590A1 (es) | Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion. | |
BRPI0819460A2 (pt) | Uso de uma proteína, composição oralmente administrável, métodos para reduzir as propriedades de erosão dental, e para reduzir a erosão dental | |
EA200970167A1 (ru) | Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина | |
BRPI0823286A2 (pt) | Dois tipos de formas cristalinas de pinocembrina, sua preparação e seu uso para a fabricação de composições farmacêuticas. | |
ITPD20050346A1 (it) | Uso di nuovi composti endocannabinoido simili,nonche' metodo di preparazione e composizioni farmaceutiche ottenibili con gli stessi | |
BRPI0702869A2 (pt) | formas cristalinas da o-desmetilvenlafaxina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |